Delivery Order SPE2DR25D1053-SPE2DR26FT826
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xeomin 100 unit vials valued at $6,704.88 with a firm fixed price structure. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a $93,868.32 firm fixed-price delivery order for 200-unit vials of Xeomin on October 17, 2025, with an ultimate completion date of November 7, 2025. This non-competitive delivery order is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Xeomin 200 Unit Vials, with a ceiling value of $23,553.20 and an ultimate completion date of December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for the supply of Xeomin 100 unit vials. The contract is valued at $2,793.70 and carries a firm fixed price structure with an ultimate completion date of August 13, 2025. This non-set-aside award represents a competitive procurement action and will be performed at the contractor's Conshohocken facility....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Xeomin 200 Unit Vials valued at $7,065.96, with completion scheduled for November 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $59,699.64 by the Defense Logistics Agency (DLA) on August 6, 2025. The contract, utilizing firm fixed-price pricing, covers the supply of Xeomin 100 unit vials and is scheduled for completion by August 27, 2025. The award was made through open competition with no set-aside designation, with performance taking place at the vendor's corporate office...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $7,542.99 firm fixed price delivery order by the Defense Logistics Agency's Medical Supply Chain on November 10, 2025, with an ultimate completion date of November 21, 2025. The award covers the supply of Xeomin 100 Unit vials and represents a competitively awarded, non-set-aside contract. This delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $33,524.40 delivery order to AmerisourceBergen Drug Corp for the supply of Xeomin 200 unit vials, with an ultimate completion date of November 24, 2025. This competitive award, issued on October 31, 2025, utilizes firm fixed pricing and does not include a set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $13,409.76 to AmerisourceBergen Drug Corp for the supply of Xeomin 200 Unit Vials, with a completion date of September 4, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively on August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This delivery order falls under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xeomin 100 unit vials, valued at $23,467.08, with an ultimate completion date of October 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT826Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Xeomin 100 unit vials, with a ceiling value of $17,664.60 and firm fixed pricing. This is a non-set-aside contract with an ultimate completion date of December 4, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is a critical federal vendor specializing in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. The company's extensive portfolio of competitively awarded federal contracts with the DLA demonstrates its capability to fulfill diverse medical procurement requirements at various price points. This award for Xeomin, a prescription medication used for therapeutic and cosmetic applications, reflects the company's role in supporting the Defense Health Agency and other federal healthcare systems through flexible contract vehicles that enable efficient medical supply chain management.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.7k | 11/12/25 |